Table 2 Use of immunosupressive drugs in patients with active lupus nephritis (LN) and inactive LN patients
From: Urinary CD8+ T-cell counts discriminate between active and inactive lupus nephritis
| Â | Active LN | Inactive LN | P-value |
|---|---|---|---|
Total number | 22 | 24 | Â |
Treatment, n | Â | Â | Â |
   None | 8 | 3 | 0.038 |
   Glucocorticoids | 10 | 13 |  |
   Median dose (range), dose (mg/day) | 5 (2.5 to 15) | 5 (1.25 to 10) |  |
Immunosupressive/immunomodulating, n | Â | Â | Â |
Hydroxychloroquine | 9 | 8 | Â |
   Median dose (range), users (mg/day) | 400 (200 to 600) | 400 (200 to 600) |  |
   Methotrexate | 1 | 2 |  |
   Median dose (range), users (mg/week) | 7.5 | 13.75 (12.5 to 15.0) |  |
   Azathioprine | 4 | 8 |  |
   Median dose (range), users (mg/day) | 100 (75 to 150) | 112.5 (75 to 150) |  |
   MMF | 1 | 3 |  |
   Median dose (range), users (mg/day) | 2,000 | 3,000 (2,000 to 3,000) |  |